Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers August 29, 2015
Pharmacy Choice - News - Over-the-Counter Drugs - August 29, 2015

Pharmacy News

 Over-the-Counter Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 23 of 23     Go To Page:

8/28/15 - Advaxis Announces Licensing Agreement With Knight Therapeutics and Raises $25 Million Through Direct Investments From Knight and Sectoral Asset... [Jerusalem Post (Israel)]
-Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the Company has entered into a licensing agreement with Knight Therapeutics Inc., a Canadian-based specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription and over-the-counter...
8/28/15 - ADVAXIS, INC. FILES (8-K) Disclosing Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
In a press release dated August 26, 2015, Advaxis, Inc. announced that it had entered into a licensing agreement with Knight Therapeutics Inc., a Canadian-based specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription and over-the-counter pharmaceutical products, to commercialize in Canada..
8/28/15 - BioElectronics Files FDA Premarket Notification for ActiPatch Therapy
By a News Reporter-Staff News Editor at Health& Medicine Week BioElectronics Corporation, maker of consumer medical electronics products for pain management, announced the filing of a 510 Premarket Notification for ActiPatch Therapy with the U.S. Food and Drug Administration. Walgreens Boots Pharmacies in the United Kingdom has chosen ActiPatc
8/28/15 - Mylan shareholders approve pursuit of Perrigo
Mylan NV's shareholders approved the company's hostile pursuit of Perrigo Co. and the generic drugmaker hopes to push ahead with a formal offer soon. Perrigo, which makes over-the-counter medicines, has resisted repeated overtures from Mylan. In April, Mylan raised its offer for Perrigo to $232.23, or about $34.1 billion, in cash and stock.
8/28/15 - Mylan shareholders back Perrigo takeover [Pittsburgh Post-Gazette]
Aug. 28 Mylan shareholders today approved the generic drug maker's proposed acquisition of The Perrigo Co. and authorized Mylan's plans to issue shares to complete the hostile transaction. Ireland- based Perrigo, which makes over-the counter drugs, has opposed the takeover from the start, saying Mylan's bid undervalues the company. Perrigo chairm
8/28/15 - Mylan shareholders endorse proposed acquisition of Perrigo, expects to make formal offer soon
NEW YORK Mylan NV's shareholders approved the proposed buyout of Perrigo Co. and the generic drugmaker hopes to push ahead with a formal offer soon.
8/28/15 - Sunovion Announces FDA Approval of a New Indication for Aptiom (eslicarbazepine acetate) as Monotherapy for Partial-Onset Seizures
Sunovion Pharmaceuticals Inc. announced today that the U.S. Food and Drug Administration approved the supplemental New Drug Application for Aptiom as monotherapy for the treatment of partial-onset seizures. Previously approved in 2013 by the FDA as adjunctive therapy for partial-onset seizures, APTIOM is the only exclusively once-daily...
8/27/15 - U.S. FDA approves Synjardy (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes
RIDGEFIELD, Conn. and INDIANAPOLIS, Aug. 27, 2015/ PRNewswire/ The U.S. Food and Drug Administration has approved Synjardy tablets, from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company, for the treatment of adults with type 2 diabetes. SYNJARDY is the third product containing empagliflozin to be approved by the FDA, follow
8/26/15 - Advaxis Announces Licensing Agreement With Knight Therapeutics and Raises $25 Million Through Direct Investments From Knight and Sectoral Asset Management
Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the Company has entered into a licensing agreement with Knight Therapeutics Inc., a Canadian-based specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription and over-the-counter...
8/26/15 - AED 497.8 Million, the Total Profit of Julphar for the Second Quarter [Kippreport (Dubai)]
Ras Al Khaimah, United Arab Emirates, 23 rd August, 2015 Julphar announced sales revenue worth AED 799.5 million in the first half of this year, with a growth of 5% compared to the same period of 2014. The company's financial results, which were shared within the Board of Director's report, showed a total profit of AED 497.8 million, up 9% yoy.
8/26/15 - Alvogen To Buy Product Portfolio From Pfizer For U.S. Market
NEW YORK CITY- Privately-held pharmaceutical company Alvogen said Wednesday that it has agreed to acquire from Pfizer Inc. a portfolio of four pharmaceutical products in the U.S., noting that the acquisition will further diversify and strengthen its commercial platform in the U.S. market. The company has commercial operations in 35 countries with 2
8/26/15 - Chinese Pharmaceuticals Market: Trends, Reforms, Opportunities and Revenue Prospects 2015-2025
Pharma Sales in China- How to Assess Trends and Potential Revenues, Benefiting Your Influence. China retains great potential for sales of prescription drugs and OTC medicines. Forecasts and other analyses to help you stay ahead on China' s pharma market.
8/26/15 - GB Pharma and Other Killers [opinion]
The Food and Drugs Authority has reportedly caught GB Pharma, a foreign-owned pharmaceutical company based in Ghana, of criminally attempting to repackage and sell to the unsuspecting public, drugs destroyed during the July 3, 2015 flood and fire disaster that occurred in Accra. According to the "Graphic" story, the Chief Executive Officer of the F
8/26/15 - Perrigo, Mylan leaders spar as vote looms [Pittsburgh Post-Gazette]
Aug. 26 Mylan and Perrigo Co. are taking their last swings at each other in the final days before Mylan shareholders vote on whether the generic drug maker should make a formal tender offer for Perrigo, an Irish over-the-counter drug specialist that opposes the hostile bid. "Perrigo continues to make misleading comments with regard to Mylan's of
8/26/15 - Shanghai Pharmaceuticals Achieves Steady Growth of Revenue and Profit for 1H2015
Laid Down Foundation for Achieving a Revenue of Over RMB100 Billion HONG KONG, Aug 26, 2015 Shanghai Pharmaceuticals Holding Co., Ltd., the pharmaceutical group in the PRC that has leading positions in both pharmaceutical product and distribution markets, today announced its interim results for the first half of 2015. In the first half of 2015, a
8/25/15 - FDA expands use of Novartis drug Promacta to include treatment of children ages 1 and older with chronic immune thrombocytopenia
Release date- 24082015- Basel,- Novartis announced today that the US Food and Drug Administration has approved an expanded use for Promacta to include children 1 year of age and older with chronic immune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promacta was approved by the FDA as a t
8/25/15 - What's New and What's Tried and True? Natural Aphrodisiacs: a Review of Selected Sexual Enhancers, Moisturizers and Lubes According to Michael Krychman, MD, Southern California Center for Sexual Health
The Food and Drug Administration defines an aphrodisiac drug product as any product that bears labeling claims that it will arouse or increase sexual desire, or that it will improve sexual performance. While the FDA approved prescription Addyi to increase sexual desire in women, many doctors recommend natural and over-the-counter remedies tha
8/24/15 - Acura Pharmaceuticals Announces 1-for-5 Reverse Stock Split
Acura Pharmaceuticals Inc., announced today that it will effect a 1- for-5 reverse stock split of its common stock. The reverse stock split is intended to increase the market price per share of the Company's common stock to allow the Company to maintain the listing of its common stock on The NASDAQ Capital Market. The Company's common stock will co
8/24/15 - AED 497.8 Million, the Total Profit of Julphar for the Second Quarter [Mid-East.Info]
Ras Al Khaimah, United Arab Emirates: Julphar announced sales revenue worth AED 799.5 million in the first half of this year, with a growth of 5% compared to the same period of 2014. The company's financial results, which were shared within the Board of Director's report, showed a total profit of AED 497.8 million, up 9% yoy. Julphar also successfu
8/24/15 - FDA expands use of Novartis drug Promacta to include treatment of children ages 1 and older with chronic immune thrombocytopenia
Novartis announced today that the US Food and Drug Administration has approved an expanded use for Promacta to include children 1 year of age and older with chronic immune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promacta was approved by the FDA as a tablet formulation in June 2
8/24/15 - FDA Expands Use of Promacta to Include Treatment of Children Ages 1 and Older with Chronic Immune Thrombocytopenia
Ligand Pharmaceuticals Incorporated today announces that the FDA has approved an expanded use for Promacta , a Novartis product, to include children 1 year of age and older with chronic immune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. The updated label also includes a new oral suspe
8/24/15 - GNW-News: FDA expands use of Novartis drug Promacta to include treatment of children ages 1 and older with chronic immune thrombocytopenia (english)
FDA expands use of Novartis drug Promacta to include treatment of children ages 1 and older with chronic immune thrombocytopenia. Novartis International AG/ FDA expands use of Novartis drug Promacta to include treatment of children ages 1 and older with chronic immune thrombocytopenia. Processed and transmitted by NASDAQ OMX Corporate Solutio
8/23/15 - Tips for how to reduce your medication costs Savvy Senior [Capital (Annapolis, MD)]
Dear Savvy Senior, Can you recommend any tips to help me save on my medication costs? I currently take five different prescription medications that are very expensive even with insurance.- Searching Susan. Here are a few strategies that can help, whether you are covered by employer-based health insurance, a health plan on the individual marketplace
Articles(s): 1 - 23 of 23     Go To Page:


© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Pharmacy Spanish
This lesson is supported by:
Hands on Spanish
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415